Bispecific Targeting CD3 and BCMA Reflect Expanding Options in Multiple Myeloma
Bispecific antibodies targeting BCMA have shown efficacy in relapsed refractory multiple myeloma, including bispecifics targeting BCMA x CD3.
Read More
Navigating the Intersection of Radiation Therapy and Immunotherapy in Endometrial Cancer
As Orthopedic Oncology Evolves, Caring for the Clinician Must Be a Priority
Belumosudil Produces Long-Term Responses Without New Safety Concerns in cGVHD
Prophylactic Itacitinib May Safely Mitigate CRS Following Axi-Cel Administration in Lymphoma